PRODUCT PIPELINE

our focus

Problem & Opportunity

No FDA approved drugs

  • Proven animal models for rapid screening
  • Local delivery method improves outcomes with fewer off-target concerns
  • Federal funding for initial studies 
  • Team of recognized experts across range of auditory maladies 

three men carrying
Product Pipelines

Robust pipeline for science-based solutions to hearing disorders

We have developed animal model systems for pre-clinical trials of drug candidates and have advanced our leading drug candidate to a clinical Phase II trial with the US Army. NIH-supported research is now enabling us to move additional candidates through our discovery pipeline.

Three Indications

Tinnitus

Tinnitus is the number one disability claim for military personnel

Hearing Loss

Prevalence of hearing loss and tinnitus in military population are greater than in the general public

Meniere’s disease

Characterized by fluctuating hearing loss, often debilitating vertigo, and roaring tinnitus that occurs in an episodic fashion. It’s estimated that there are 600,000-750,000 cases of Ménière’s disease in the United States

Products

4
Patents Filed
7
Papers Published
9
SBIR/STTR Grants Received

Our Strategy

New Drug Development

Utilizing 505(b)(2) regulatory pathway to repurpose FDA-approved drugs as tinnitus therapies

GW-TT2

Recently received positive feedback from FDA in preIND meeting for product development strategy

Targeted Delivery

Utilizing Adeno-Associated Virus (AAV)-based tools to target cells in the auditory pathway (or auditory system) as a tinnitus therapy

GW-TT5

Promising pre-clinical animal studies demonstrate that we are able to manipulate the tinnitus symptoms with gene therapy